Table 3.
Prospective studies on HBV reactivation in malignant lymphoma patients.
| Study | Taiwan (2014) [16] | Hong Kong (2014) [17] | Japan (2015) [18] | China (2019) [36] |
|---|---|---|---|---|
| Number of patients | 150 | 70 | 269 | 190 (prophylactic group: 95, preemptive group: 95) |
| Chemotherapy | R-CHOP | R containing regimens | R-steroid-containing regimens | Various regimens (R-containing regimens: 74.7%) |
| Definition of HBV reactivation | HBV DNA level; greater than 10-fold increase | HBV DNA level >10 IU/mL (1.7 log copies/mL) | HBV DNA level >11 IU/mL (1.8 log copies/mL) | Reappearance of HBsAg and HBV DNA |
| HBV DNA level; cut-off | 3.0 log copies/mL | 10 IU/mL (1.7 log copies/mL) | 11 IU/mL (1.9 log copies/mL) | 50 IU/mL |
| Duration from initiation of chemotherapy to HBV reactivation, median (range) | 5.3 months (0.8–14.3) | 6.0 months (1.0–25.0) | 3.2 months (1.0–16.3) | 6.0 months (2.0–7.0) |
| HBV reactivation | 11.3% (17 of 150) | 30.2% (19 of 63) | 8.2% (22 of 269) | 0% in prophylactic group 3.2% (3/95) in preemptive group |
| Cumulative incidence rate of HBV reactivation | 10.4/100 person-year | 41.5%/2 years | 8.3%/1.5 years | N/A |
| Hepatitis | 6.7% (10 of 150) | 0% | 0% | 0% in prophylactic group 1.1% (1/95) in preemptive group |
| HBV reactivation related death | 0% | 0% | 0% | 0% |
Abbreviations: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.